Cordica Bolsters Micron-Precision Molding! Acquisition Fills Gap In Small-Scale Medical Device Component Manufacturing

Medical device contract research and manufacturing service provider Cordica Medical recently completed the acquisition of the micro injection molding business segment of RapidWerks, thereby strengthening its production capacity to meet the increasing market demand for micron-level precision miniaturized medical device components. The specific terms of the transaction have not been disclosed.

RapidWerks Inc., headquartered in Pleasanton, California, specializes in precision injection molding, micro injection molding, insert molding, mold manufacturing, and contract assembly, serving end markets in medical devices such as orthopedics, cardiovascular, neurology, and pharmaceuticals.

Cordica Floor-Standing Micro Injection Molding Complete Equipment

This acquisition adds a dedicated fully automated micro-injection molding production equipment to Cordica's integrated R&D and manufacturing platform. The core model is a top-tier fully automated micro-injection molding machine from Europe, with supporting technology mastered by only a very limited number of manufacturers worldwide. The equipment ensures stable and controllable injection volume accuracy, enabling mass production of parts with single weights as low as a few tenths of a gram, and excellent product consistency.

This strategic acquisition enables Cordica to mass-produce a wide range of high-precision micro-injection-molded medical device components for customers focused on product miniaturization and functional integration. Building on Cordica’s existing production capacity for interventional and critical care medical devices, the addition of micro-injection molding completes the entire value chain, allowing the company to provide customers with complete finished devices and integrated medical products ready for direct use. The expanded capacity not only meets current market order demand but also reserves ample room for future business growth.

Marshall White, CEO of Cordica Medical, stated, "Micro-injection molding is a key part of our technological layout. With our global production network and the integration of this process into our vertically integrated platform, clients can collaborate with a single responsible entity to achieve the full process of turning medical device designs into large-scale precision production."

Full-Industry-Chain Platform Strength Upgrade

This acquisition enhances Cordica's one-stop service system, expanding its injection molding capabilities into the realm of micrometer tolerance precision processing and adding forming processes for high-performance, difficult-to-process materials such as PEEK and bioabsorbable polymers. The entire micro injection molding process is certified under the ISO 13485 system and includes an online visual inspection procedure. Medical device manufacturers can rely on a single partner to complete the entire product lifecycle from R&D project initiation to commercial mass production, meeting the stringent requirements for processing accuracy, compliance control, and supply chain stability for the next generation of devices.

RapidWerks founder Scott Herbert, who joined Cordica after the transaction closed, said: “Precision micro injection molding has an extremely low margin for error. Part specifications, tolerance standards, raw material selection, and production scale must all work together to meet requirements. Leveraging Cordica’s industrial footprint in the United States and globally, our technology can empower more customers and open up entirely new application scenarios across the medical device industry.”

According to information on its official website, Cordica is headquartered in Knoxville, Tennessee, with 19 manufacturing facilities across the United States and additional overseas plants in Mexico and Singapore. The company focuses on essential medical consumables, offering end-to-end customized R&D and manufacturing services. Upholding the business philosophy of “turning designs into reality and delivering finished products,” it has established a comprehensive advanced intelligent manufacturing system. Its business spans multiple end markets, including minimally invasive surgery, in vitro diagnostics, drug delivery, infection prevention and control, vital signs monitoring, and advanced wound care.